74
Mostly True
United States
The website reports that Philips' Rembra platform has received FDA clearance, enabling high-throughput imaging and precision in cancer care. The Rembra CT can support up to 270 exams per day, and the Rembra RT and Areta RT offer high-fidelity imaging for treatment planning.
The claims regarding Philips' Rembra platform receiving FDA clearance and its capabilities are well-supported by multiple sources, including Philips' official announcements and reputable industry publications. The evidence confirms the FDA clearance and the platform's high-throughput imaging capabilities, supporting up to 270 exams per day and providing high-fidelity imaging for treatment planning. However, the claim about the FDA clearance strengthening Philips' portfolio is an opinion and not verifiable as a factual assertion.
Individual Claims
86
True
Technology
Royal Philips has received 510(k) clearance from the U.S. Food and Drug Administration for its Rembra platform of scanning systems.
Multiple sources confirm that Royal Philips received 510(k) clearance from the FDA for its Rembra platform, including Rembra CT, Rembra RT, and Areta RT. This is supported by evidence from Philips' official press release and other reputable sources like Applied Radiology.
Fact Check Score
None
Fact Check Weight
0
Web Consensus Score
95
Web Consensus Weight
50
Source Quality Score
90
Source Quality Weight
25
Llm Reasoning Score
90
Llm Reasoning Weight
25
Weighted Total
86
Evidence Summary
Multiple web sources confirm FDA clearance for Philips' Rembra platform.
77
Mostly True
Healthcare
The Rembra platform enables high-throughput imaging at scale and elevates precision across the cancer care pathway.
The claim is supported by multiple sources that describe the Rembra platform's capabilities for high-throughput imaging and precision in cancer care. These include Philips' press release and Imaging Technology News, which confirm the platform's design for high-demand environments.
Fact Check Score
None
Fact Check Weight
0
Web Consensus Score
85
Web Consensus Weight
50
Source Quality Score
80
Source Quality Weight
25
Llm Reasoning Score
80
Llm Reasoning Weight
25
Weighted Total
77
Evidence Summary
Multiple sources confirm high-throughput imaging and precision capabilities of the Rembra platform.
81
True
Healthcare
Rembra CT supports up to 270 exams per day.
The claim is corroborated by several sources, including Philips' press release and Imaging Technology News, which state that the Rembra CT system can handle up to 270 exams per day. This is consistent across multiple reports.
Fact Check Score
None
Fact Check Weight
0
Web Consensus Score
90
Web Consensus Weight
50
Source Quality Score
85
Source Quality Weight
25
Llm Reasoning Score
85
Llm Reasoning Weight
25
Weighted Total
81
Evidence Summary
Multiple sources confirm Rembra CT supports up to 270 exams per day.
77
Mostly True
Healthcare
Rembra RT and Areta RT support high-fidelity imaging for treatment planning with a wide 85 cm extended field of view.
The claim is supported by evidence from Philips and other sources, which confirm that Rembra RT and Areta RT provide high-fidelity imaging with an 85 cm field of view, enhancing treatment planning capabilities.
Fact Check Score
None
Fact Check Weight
0
Web Consensus Score
85
Web Consensus Weight
50
Source Quality Score
80
Source Quality Weight
25
Llm Reasoning Score
80
Llm Reasoning Weight
25
Weighted Total
77
Evidence Summary
Multiple sources confirm high-fidelity imaging and 85 cm field of view for Rembra RT and Areta RT.
50
Mixed
Business
The FDA clearances further strengthen Philips’ comprehensive CT portfolio.
This claim is an opinion about the impact of FDA clearance on Philips' portfolio and cannot be objectively verified. It reflects a subjective assessment rather than a factual assertion.
Fact Check Score
None
Fact Check Weight
0
Web Consensus Score
None
Web Consensus Weight
0
Source Quality Score
None
Source Quality Weight
0
Llm Reasoning Score
50
Llm Reasoning Weight
100
Weighted Total
50
Evidence Summary
Claim is an opinion and not subject to factual verification.
